Assembly Biosciences, Inc. Increase (Decrease) in Contract with Customer, Liability
Assembly Biosciences, Inc. (ASMB) reported Increase (Decrease) in Contract with Customer, Liability of -$20.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-13
- Assembly Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$12.77M.
- Assembly Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$7.83M.
- Assembly Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$7.17M, a 191.17% decline year-over-year.
- Assembly Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$9.88M.
- Assembly Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$36.10M.
- Assembly Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$13.29M, a 115.91% decline from fiscal 2023.
- Assembly Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $83.56M.
- Assembly Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$20.60M 10-Q · filed 2026-08-13 | -$27.77M derived: sum of 3 quarters · filed 2026-08-13 | -$37.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$7.83M 10-Q · filed 2026-05-07 | -$15.00M derived: sum of 2 quarters · filed 2026-05-07 | -$24.88M derived: sum of 3 quarters · filed 2026-05-07 | -$34.51M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$7.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$17.05M derived: sum of 2 quarters · filed 2026-03-19 | -$26.68M derived: sum of 3 quarters · filed 2026-08-13 | -$36.10M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$9.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$19.50M derived: sum of 2 quarters · filed 2026-08-13 | -$28.92M 10-Q · filed 2025-11-10 | -$21.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$9.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$19.05M 10-Q · filed 2026-08-13 | -$11.18M derived: sum of 3 quarters · filed 2026-08-13 | -$18.02M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$9.42M 10-Q · filed 2026-05-07 | -$1.55M derived: sum of 2 quarters · filed 2026-05-07 | -$8.39M derived: sum of 3 quarters · filed 2026-05-07 | -$16.93M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.02M derived: sum of 2 quarters · filed 2026-03-19 | -$7.51M derived: sum of 3 quarters · filed 2026-03-19 | -$13.29M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$6.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$15.38M derived: sum of 2 quarters · filed 2025-11-10 | -$21.16M 10-Q · filed 2025-11-10 | $62.40M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$8.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$14.32M 10-Q · filed 2025-08-06 | $69.24M derived: sum of 3 quarters · filed 2025-08-06 | $69.24M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$5.79M 10-Q · filed 2025-05-08 | $77.78M derived: sum of 2 quarters · filed 2025-05-08 | $77.78M derived: sum of 3 quarters · filed 2025-05-08 | $77.78M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $83.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $83.56M derived: sum of 2 quarters · filed 2025-03-20 | $83.56M derived: sum of 3 quarters · filed 2025-03-20 | $83.56M 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2024-05-08 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$6.25M derived: sum of 2 quarters · filed 2023-03-22 | -$6.25M derived: sum of 3 quarters · filed 2023-03-22 | -$6.25M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$6.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$6.25M derived: sum of 2 quarters · filed 2022-11-08 | -$6.25M 10-Q · filed 2022-11-08 | -$6.25M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | $0.00 derived: sum of 3 quarters · filed 2022-03-11 | $8.99M derived: sum of 4 quarters · filed 2022-03-11 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $8.99M derived: sum of 3 quarters · filed 2022-03-11 | -$27.05M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $8.99M derived: sum of 2 quarters · filed 2022-03-11 | -$27.05M derived: sum of 3 quarters · filed 2022-03-11 | -$28.06M 10-K · filed 2022-03-11 |
| 2020-09-30 | $8.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$27.05M derived: sum of 2 quarters · filed 2021-11-04 | -$28.06M 10-Q · filed 2021-11-04 | -$29.43M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$36.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$37.05M 10-Q · filed 2021-08-05 | -$38.42M derived: sum of 3 quarters · filed 2021-08-05 | -$39.66M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$1.01M 10-Q · filed 2021-05-06 | -$2.38M derived: sum of 2 quarters · filed 2021-05-06 | -$3.62M derived: sum of 3 quarters · filed 2021-05-06 | -$3.76M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$2.62M derived: sum of 2 quarters · filed 2021-02-25 | -$2.75M derived: sum of 3 quarters · filed 2021-02-25 | -$3.61M 10-K · filed 2021-02-25 |
| 2019-09-30 | -$1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$1.38M derived: sum of 2 quarters · filed 2020-11-05 | -$2.24M 10-Q · filed 2020-11-05 | -$3.50M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$137.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$996.00K 10-Q · filed 2020-08-05 | -$2.26M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$859.00K 10-Q · filed 2020-05-08 | -$2.12M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | -$1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$5.13M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | -$3.86M 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $45.78M 10-K · filed 2020-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |